BPG is committed to discovery and dissemination of knowledge
Articles in Press
9/17/2026 9:37:45 AM | Browse: 6 | Download: 0
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Cardio-hepatic axis in metabolic dysfunction-associated steatotic liver disease: Mechanisms, clinical implications and therapeutic opportunities
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ran Zhao, Jia-Lian Zheng, Yan Wang, Bing-Jiu Lu, Yan Zhang and Bao-Cheng Deng |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
82174241 |
|
| Corresponding Author |
Bao-Cheng Deng, Department of Infectious Diseases, The First Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning Province, China. bcdeng@cmu.edu.cn |
| Key Words |
Metabolic dysfunction-associated steatotic liver disease; Cardio-hepatic axis; Cardiovascular disease; Risk stratification; Therapeutic strategies |
| Core Tip |
Metabolic dysfunction-associated steatotic liver disease is a systemic cardiometabolic disorder driven by the cardio-hepatic axis. This review examines bidirectional signaling and systemic amplification networks within this axis and explores its intrinsic mechanisms. Based on population evidence, we propose a risk stratification framework that integrates metabolic dysfunction-associated steatotic liver disease evaluation into cardiovascular risk assessment, shifting management from a liver-centric to a systemic cardio-hepatic co-management model. We also critically appraise therapeutic strategies targeting these mechanisms according to clinical evidence strength. However, key challenges remain, including the liver-heart causal relationship, the lack of a risk assessment system capturing cardio-hepatic crosstalk, and the limited availability of axis-specific randomized controlled trials. |
| Citation |
Zhao R, Zheng JL, Wang Y, Lu BJ, Zhang Y, Deng BC. Cardio-hepatic axis in metabolic dysfunction-associated steatotic liver disease: Mechanisms, clinical implications and therapeutic opportunities. World J Hepatol 2026; In press
|
 |
Received |
|
2026-06-29 03:22 |
 |
Peer-Review Started |
|
2026-06-29 03:22 |
 |
First Decision by Editorial Office Director |
|
|
 |
Return for Revision |
|
2026-07-21 02:54 |
 |
Revised |
|
2026-08-04 00:32 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2026-09-17 02:42 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2026-09-17 09:37 |
 |
Articles in Press |
|
2026-09-17 09:37 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.